期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021
卷 61, 期 -, 页码 65-84出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-030920-025745
关键词
pharmacogenomics; pharmacogenetics; clinical implementation; adverse drug reaction; drug safety; drug effectiveness
The clinical implementation of pharmacogenetic biomarkers is growing as new genetic variants associated with drug outcomes are discovered. Incorporating pharmacogenetic information into healthcare improves drug safety and reduces empiricism in drug selection. However, barriers to the implementation of pharmacogenetic testing remain.
The clinical implementation of pharmacogenetic biomarkers continues to grow as new genetic variants associated with drug outcomes are discovered and validated. The number of drug labels that contain pharmacogenetic information also continues to expand. Published, peer-reviewed clinical practice guidelines have also been developed to support the implementation of pharmacogenetic tests. Incorporating pharmacogenetic information into health care benefits patients as well as clinicians by improving drug safety and reducing empiricism in drug selection. Barriers to the implementation of pharmacogenetic testing remain. This review explores current pharmacogenetic implementation initiatives with a focus on the challenges of pharmacogenetic implementation and potential opportunities to overcome these challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据